Drug intelligence / Profile preview

yhd001

Development stage: Phase 2
Lead developer: Yuhan
Modality: Small Molecules

Overview

YHD001 is a small molecule drug initially developed by Yuhan Corporation for the treatment of immune system diseases, infectious diseases, and respiratory diseases. It has been investigated in clinical trials for acute bronchitis, chronic bronchitis, and asthma. The mechanism of action is not fully defined but it is classified as an antibronchitic agent. Clinical development included randomized, double-blind, placebo/active-controlled studies comparing different doses of YHD001 to standard treatments such as montelukast (Singulair) or pelargonium sidoides extract[2][3][6].

Beyond the preview

Go deeper on yhd001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on yhd001.

Explore the full profile